154 related articles for article (PubMed ID: 33729079)
1. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer.
Kim H; Vargo JA; Beriwal S; Clump DA; Ohr JP; Ferris RL; Heron DE; Huq MS; Smith KJ
Head Neck; 2018 Aug; 40(8):1743-1751. PubMed ID: 29537684
[TBL] [Abstract][Full Text] [Related]
3. Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.
van der Linden N; van Gils CW; Pescott CP; Buter J; Vergeer MR; Groot CA
Eur Arch Otorhinolaryngol; 2015 Aug; 272(8):2007-16. PubMed ID: 24943191
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Leung HW; Liu CF; Chan AL
Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis.
Ye D; Liang X; Chen X; Li Y
Sci Rep; 2024 Mar; 14(1):6807. PubMed ID: 38514766
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis.
Chan AL; Leung HW; Huang SF
Clin Drug Investig; 2011 Oct; 31(10):717-26. PubMed ID: 21744880
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of patient-reported quality-of-life outcomes following SBRT ± cetuximab for locally-recurrent, previously-irradiated head and neck cancer.
Vargo JA; Heron DE; Ferris RL; Rwigema JC; Wegner RE; Kalash R; Ohr J; Kubicek GJ; Burton S
Radiother Oncol; 2012 Jul; 104(1):91-5. PubMed ID: 22677037
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
[TBL] [Abstract][Full Text] [Related]
12. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
[TBL] [Abstract][Full Text] [Related]
14. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.
Vargo JA; Ferris RL; Ohr J; Clump DA; Davis KS; Duvvuri U; Kim S; Johnson JT; Bauman JE; Gibson MK; Branstetter BF; Heron DE
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):480-8. PubMed ID: 25680594
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer.
Huang TL; Chuang HC; Tsai MH; Chien CY; Su YY; Lin YT; Yang CH; Lai CC; Li SH; Fang FM
Biomed J; 2022 Oct; 45(5):838-846. PubMed ID: 34749016
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
[No Abstract] [Full Text] [Related]
17. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
She L; Tian K; Han J; Zuo W; Wang Z; Zhang N
Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Griffin S; Walker S; Sculpher M; White S; Erhorn S; Brent S; Dyker A; Ferrie L; Gilfillan C; Horsley W; Macfarlane K; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():49-54. PubMed ID: 19567214
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]